Cat. No.: HY-P1206

CH 275

Name: CH 275
Brand: MedChemExpress
SKU: HY-P1206
Price: 145.00 USD
Availability: InStock
Rating: 5 (1 reviews)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

CH 275 is a peptidic somatostatin analog that acts as an agonist of SST1 (IC₅₀ = 30.9 nM, K_i = 52 nM). The IC₅₀ values of CH 275 for sst3, sst4, sst2, and sst5 are 345 nM, >1 μM, >10 μM, and >10 μM, respectively. CH 275 binds to SSTR1 via the IAmp9-Asp137 ion pair interaction and the hydrophobic interaction between the isopropyl group of IAmp9 and Leu107, and reduces the extracellular acidification rate. CH 275 induces weak sst1 internalization, exerts immunosuppressive effects on macrophages, and decreases macrophage viability, MCP-1 expression/secretion, and IL-8 secretion, but does not alter proMMP-9 secretion or IL-8 mRNA levels. CH 275 reduces hippocampal β-amyloid levels and alleviates plaque pathology without inducing hippocampal microglial activation. CH 275 is used in research on Alzheimer's disease, Parkinson's disease, and depression.

For research use only. We do not sell to patients.

Purity: 99.52%
CAS No.: 174688-78-9
Formula: C₇₄H₉₆N₁₄O₁₅S₂
Molecular Weight:1485.77

Storage:

Sealed storage, away from moisture and light.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

CH 275 Chemical Structure

CAS No.: 174688-78-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

SSTR1

All Somatostatin Receptor Isoforms :

In Vitro

CH 275 (1 μM; 24 h) potently reduces viability of LPS-activated human macrophages differentiated from PBMC-derived monocytes by 78% via an sst₁-mediated mechanism^[1].
CH 275 (1 μM; 24 h) induces weak internalization of sst₁ receptors in LPS-activated human macrophages differentiated from PBMC-derived monocytes after 24 h of treatment^[1].
CH-275 (1 μM; 24 h) does not affect proMMP-9 secretion from LPS-activated human macrophages differentiated from PBMC-derived monocytes^[1].
CH 275 (1 μM; 24 h) decreases both MCP-1 mRNA expression and secreted MCP-1 protein in LPS-activated human macrophages differentiated from PBMC-derived monocytes^[1].
CH 275 (1 μM; 24 h) reduces IL-8 secretion without affecting IL-8 mRNA levels in LPS-activated human macrophages differentiated from PBMC-derived monocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

LPS-activated human macrophages differentiated from PBMC-derived monocytes
Concentration:

1 μM
Incubation Time:

24 h
Result:

Decreased basal absorbance (a measure of viable cell number/metabolic activity) by 78%.
Showed viability-reducing effect that was completely reversed by co-application of the sst₁-selective antagonist SRA-880.

Immunofluorescence^[1]

Cell Line:

LPS-activated human macrophages differentiated from PBMC-derived monocytes
Concentration:

1 μM
Incubation Time:

24 h
Result:

Induced weak punctate sst₁ immunoreactivity inside cells in addition to surface-localized receptor, indicating a weak level of sst₁ receptor internalization.

In Vivo

Intracerebroventricular infusion of CH275 (56 µM; i.c.v.; continuous; 4 months) in App^NL-G-F mice increases hippocampal neprilysin expression, reduces Aβ pathology, and reduces anxiety-like behavior^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (AppNL-G-F knock-in; 2 months of age at start of administration)^[4]
Dosage:

56 µM (infusate concentration); 2 µM (measured total hippocampal concentration); 100 nM (targeted interstitial fluid concentration)
Administration:

i.c.v. (brain infusion cannula connected to osmotic pump); continuous; 4 months; flow rate 0.11 µl/h
Result:

Robustly increased neprilysin expression in the ipsilateral hippocampus compared to the contralateral side.
Reduced Aβ levels on the ipsilateral side.
Showed a trend toward improved memory performance in the Y-maze.
Significantly reduced anxiety level in the open field test.
Showed no significant difference in microglial activation compared to PBS-injected mice in either the ipsilateral or contralateral hippocampus via Iba1 staining.
Caused no toxic side effects.

Chemical Information

CAS No. 174688-78-9
Appearance Solid
Molecular Weight 1485.77
Formula C₇₄H₉₆N₁₄O₁₅S₂
Color White to off-white
Sequence

Cys-Lys-Phe-Phe-{d-Trp}-Phe-Thr-Phe-Thr-Ser-Cys (Modifications: Cyclic Cys1-Cys11, X=4-[[(1-methylethyl)amino]methyl]-Phe)
Sequence Shortening

CKFF-{d-Trp}-XTFTSC (Modifications: Cyclic Cys1-Cys11, X=4-[[(1-methylethyl)amino]methyl]-Phe)
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

2025 Sep 3.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (67.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (33.65 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.6731 mL

3.3653 mL

6.7305 mL

5 mM

0.1346 mL

0.6731 mL

1.3461 mL

10 mM

0.0673 mL

0.3365 mL

0.6731 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (294 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Armani C, et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. Journal of leukocyte biology. 2007 Mar;81(3):845-55.

[2]. Chen L, et al. Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin. Biochemical and biophysical research communications. 1999 May 19;258(3):689-94. [Content Brief]

[3]. Vasilaki A, et al. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat. Neuropharmacology. 2004 Sep;47(4):612-8.

[4]. Nilsson P, et al. Somatostatin receptor subtypes 1 and 4 regulate neprilysin, the major amyloid-β degrading enzyme in brain. Journal of Alzheimer's disease : JAD. 2026 Jan;109(2):651-666.

[5]. Rivier JE, et al. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J Med Chem. 2001 Jun 21;44(13):2238-46. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.6731 mL	3.3653 mL	6.7305 mL	16.8263 mL
	5 mM	0.1346 mL	0.6731 mL	1.3461 mL	3.3653 mL
	10 mM	0.0673 mL	0.3365 mL	0.6731 mL	1.6826 mL
	15 mM	0.0449 mL	0.2244 mL	0.4487 mL	1.1218 mL
	20 mM	0.0337 mL	0.1683 mL	0.3365 mL	0.8413 mL
	25 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6731 mL
	30 mM	0.0224 mL	0.1122 mL	0.2244 mL	0.5609 mL
DMSO	40 mM	0.0168 mL	0.0841 mL	0.1683 mL	0.4207 mL
	50 mM	0.0135 mL	0.0673 mL	0.1346 mL	0.3365 mL
	60 mM	0.0112 mL	0.0561 mL	0.1122 mL	0.2804 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CH 275

Publications Citing Use of MedChemExpress (MCE) CH 275

All Somatostatin Receptor Isoforms